Genetic Models
Genetic Models
批准号:
10357774
负责人:
CHARLES A O'BRIEN
金额:
$19.68万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-16 至 2023-03-31
关键词:
AffectAnimal ModelAnimalsArkansasBioinformaticsBreast cancer metastasisCell LineCell modelCell physiologyCellsCenters of Research ExcellenceChildClustered Regularly Interspaced Short Palindromic RepeatsCommunitiesDNADeteriorationDevelopmentDiseaseEducational workshopEvaluationFertilization in VitroGene TargetingGene-ModifiedGenerationsGenesGenetic ModelsGoalsHealthcare SystemsHistologyHuman ResourcesImageInjectionsInstitutionLeadLeadershipLiteratureMaintenanceMedicalModelingModificationMolecularMouse Cell LineMultiple MyelomaMusMusculoskeletal DiseasesPathologic ProcessesPathway interactionsPlayProcessResearchResearch InstituteResearch PersonnelResearch Project GrantsResourcesRoleScienceServicesSignal PathwaySkeletonSystemTechnologyTestingTrainingTraining and EducationTransgenic MiceTransgenic Mouse FacilityTransgenic OrganismsUniversitiesUpdateVeteransbasecohortdesigndisease-causing mutationeffective therapygenetic analysisgenetically modified cellsmeetingsmembernew technologynovelnovel strategiesnovel therapeutic interventionnovel therapeuticsskillssperm cryopreservationsynergismtool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Each of the Project Leaders supported by the proposed Center for Musculoskeletal Disease Research
(CMDR) will require the generation of new genetically modified mice or cell lines to accomplish the goals of their
proposed studies. To serve the needs of this COBRE, a Genetic Models Core will be created by expanding an
existing transgenic mouse facility at the University of Arkansas for Medical Sciences (UAMS). This existing
facility has a strong record of producing transgenic mice. However, to meet the needs of the proposed CMDR, it
will be necessary to expand its capabilities by adding new technologies and personnel. This will be accomplished
in part using recently developed tools that are based on the CRISPR-Cas9 system to provide gene-editing
services in both mice and cell lines. This expansion of services will create a Genetic Models Core that, in addition
to meeting the needs of the COBRE Project Leaders, will provide new cutting-edge services to the research
communities at UAMS, its affiliated institutions, and across Arkansas. In Specific Aim 1, we propose to provide
state-of-the-art services for the generation and maintenance of genetically modified mice. Generation services
will include the design and creation of transgenic and gene-targeted mice by pronuclear injection. Maintenance
services will include sperm cryopreservation, in vitro fertilization, and strain rederivation. In Specific Aim 2, we
propose to develop new approaches and services that support genetic model creation and use. New services
needed by CMDR members, such as creation of genetically modified cell lines, will be developed. In addition,
Core personnel will continuously update gene-editing tools for cell and mouse modification via evaluation of
current literature and attendance at workshops and meetings. In Specific Aim 3, we propose to provide training
and education related to the use of genetic models. Project Leaders and other users will be trained to efficiently
and accurately produce experimental cohorts of genetically modified mice, and we will educate users on potential
problems that are often encountered with the use of such models. Core personnel will also educate the research
communities at UAMS and other campuses in Arkansas, about the services and technologies available through
the Genetic Models Core. The scientific theme of the proposed CMDR is that conditions that lead to deterioration
of the skeleton have a molecular basis whose identification will guide development of specific and effective
therapies. The Genetic Models Core is consistent with this theme in that it will allow Project Leaders to rapidly
and efficiently test the role of specific molecular changes in pathological processes the affect the skeleton or in
which the skeleton plays a major role, such as myeloma or breast cancer metastases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
-
批准号:10117260
-
项目类别:
-
资助金额:$49.51万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Center for Musculoskeletal Disease Research (CMDR)
-
批准号:10357772
-
项目类别:
-
资助金额:$227.44万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Administrative Core
-
批准号:10357773
-
项目类别:
-
资助金额:$51.17万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Administrative Core
-
批准号:10495742
-
项目类别:
-
资助金额:$58.84万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Genetic Models
-
批准号:10117261
-
项目类别:
-
资助金额:$19.04万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Center for Musculoskeletal Disease Research (CMDR)
-
批准号:10495741
-
项目类别:
-
资助金额:$229.5万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Center for Musculoskeletal Disease Research (CMDR)
-
批准号:10117257
-
项目类别:
-
资助金额:$227.44万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and lymphocyte-mediated bone loss
-
批准号:9275307
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and lymphocyte-mediated bone loss
-
批准号:8633709
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and Inflammation-associated Bone Loss
-
批准号:8258635
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and Inflammation-associated Bone Loss
-
批准号:7687062
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Molecular mechanisms of glucocorticoid-induced bone loss
-
批准号:10084209
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and Inflammation-associated Bone Loss
-
批准号:8195622
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and Inflammation-associated Bone Loss
-
批准号:7782821
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
TRANSGENIC MOUSE CORE
-
批准号:7094987
-
项目类别:
-
资助金额:$10.84万
-
财政年份:2006
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Osteocyte Control of Bone Remodeling
-
批准号:10442181
-
项目类别:
-
资助金额:$33.44万
-
财政年份:2003
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Osteocyte Control of Bone Remodeling
-
批准号:9236157
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2003
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Molecular Control of RANKL Gene Expression
-
批准号:7877808
-
项目类别:
-
资助金额:$31.58万
-
财政年份:2003
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Molecular Control of RANKL Gene Expression
-
批准号:7663135
-
项目类别:
-
资助金额:$31.9万
-
财政年份:2003
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Osteocyte Control of Bone Remodeling
-
批准号:8880756
-
项目类别:
-
资助金额:$32.78万
-
财政年份:2003
-
负责人:CHARLES A O'BRIEN
-
依托单位:
海外基金